Skip to content
OpenCapital
Get started

DBV Technologies DBVT Change in Other Liabilities

Change in Other Liabilities at other companies

Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$1.36M-125%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K—
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+269%
Enterprise value$700.21M+188%
P/S159.6×+89.0×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity0×-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's change in other liabilities?
DBV Technologies (DBVT) reported change in other liabilities of -$4.7M in Q1 2026.
How has DBV Technologies's change in other liabilities changed year-over-year?
DBV Technologies's change in other liabilities decreased by 51.6% year-over-year, from -$3.1M to -$4.7M.
What does change in other liabilities mean?
Change in miscellaneous liabilities affecting operating cash flow.